Core Viewpoint - Silvaco Group, Inc. will announce its financial results for Q2 2025 on August 6, 2025, and will provide a full-year outlook during a conference call [1][2]. Company Overview - Silvaco is a provider of TCAD, EDA software, and SIP solutions that facilitate semiconductor design and AI through innovative software [3]. - The company's solutions are utilized in various sectors including display, power devices, automotive, memory, high-performance computing, foundries, photonics, IoT, and 5G/6G mobile markets for complex SoC design [3]. - Silvaco is headquartered in Santa Clara, California, and has a global presence with offices in North America, Europe, Brazil, China, Japan, Korea, Singapore, and Taiwan [3]. Financial Results Announcement - The financial results for the second quarter ended June 30, 2025, will be released after market close on August 6, 2025 [1]. - A conference call will be held at 5:00 p.m. Eastern time to discuss the results and the full-year outlook [1][3]. - An earnings presentation and supplemental financial results will be available on the company's investor relations website [2]. Conference Call Details - Participants can register for the conference call to receive dial-in numbers and a unique PIN [2]. - An archived replay of the conference call will be accessible on the investor relations website for a limited time after the call [2].

Group 1 - A securities fraud investigation has been initiated into Hims & Hers Health Inc. regarding potential violations of the Securities Exchange Act of 1934, focusing on misleading information about regulatory compliance and business operations [1] - Following the termination of a collaboration with Novo Nordisk on June 23, 2025, Hims & Hers' stock experienced a decline of over 34% [2] - A class action lawsuit has been filed against Hims & Hers, alleging the company failed to disclose risks associated with its compounded drug offerings during the Class Period from April 29, 2025, to June 22, 2025 [2]

Core Insights - Viking Therapeutics reported significant clinical and financial developments in Q2 2025, including the initiation of the Phase 3 VANQUISH program for VK2735, aimed at treating obesity and type 2 diabetes [2][4] - The company ended the quarter with a strong cash position of $808 million, supporting ongoing clinical trials and development programs [5][16] Clinical Pipeline Updates - The VANQUISH Phase 3 program for VK2735 includes two studies targeting approximately 4,500 adults with obesity and 1,100 adults with type 2 diabetes, assessing the efficacy and safety of VK2735 administered weekly for 78 weeks [4][5] - The Phase 2 VENTURE-Oral Dosing study of VK2735's oral formulation completed enrollment with approximately 280 patients, with top-line results expected in the second half of 2025 [6][8] - VK2735 demonstrated statistically significant weight loss of up to 14.7% in previous trials, with a favorable safety profile [3][4] Financial Performance - Research and development expenses for Q2 2025 were $60.2 million, up from $23.8 million in Q2 2024, primarily due to increased clinical study costs [10][11] - General and administrative expenses rose to $14.4 million in Q2 2025 from $10.3 million in Q2 2024, driven by higher stock-based compensation [11] - The net loss for Q2 2025 was $65.6 million, compared to a net loss of $22.3 million in Q2 2024, reflecting increased operational costs [12] Balance Sheet Overview - As of June 30, 2025, Viking held cash, cash equivalents, and short-term investments totaling $808 million, a decrease from $903 million at the end of 2024 [16] - The total liabilities stood at $32.4 million, with stockholders' equity at $795.5 million [25]

CINCINNATI, July 23, 2025 (GLOBE NEWSWIRE) -- Mobile Infrastructure Corporation [Nasdaq: BEEP], owners of a diversified portfolio of parking assets throughout the United States, will issue its second quarter 2025 earnings release after the U.S. market closes on Tuesday, August 12, 2025. You are invited to participate in the Company’s conference call hosted by senior management on Tuesday, August 12, 2025, at 4:30 PM Eastern Time. Q2 2025 Conference Call Date & Time:Tuesday, August 12, 2025, at 4:30 PM Easte ...

Core Viewpoint - The Honest Company will report its second quarter 2025 financial results on August 6, 2025, after market close [1] Group 1: Financial Reporting - The company will host an investor conference call and webcast to discuss the financial results at 1:45 PM PT/4:45 PM ET on the same day [2] - A live webcast of the conference call will be available on the company's investor website [2] - Participants are encouraged to join the call fifteen minutes early to avoid delays [2] Group 2: Company Overview - The Honest Company is dedicated to creating cleanly-formulated and sustainably-designed personal care products across various categories including diapers, wipes, beauty, and household care [3] - Founded in 2012, the company aims to challenge industry standards through its Honest brand and mission [3]

Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company ...

New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments by way of co-optation of Dawn Svoronos and Jane Griffiths as Non-Executive Independent Directors to its Board of Directors, effective July 28, 2025. Dawn Svoronos and Jane Griffiths will replace Peter Guenter and Simon Sturge, who will step down from the Board on July 28, 2025. Jérôme Contamine, Chair o ...

Key Takeaways CVS is expected to post Q2 earnings of $1.47 per share, down 19.67% year over year. Earnings estimates dropped 11 cents over 90 days due to legal, cost and regulatory headwinds. Aetna redesigns and PBM savings efforts are expected to support segment-level Q2 performance.CVS Health Corporation (CVS) is scheduled to report second-quarter 2025 results on July 31, before the opening bell.In the last reported quarter, the company’s adjusted earnings of $2.25 exceeded the Zacks Consensus Estimate ...

WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the call and th ...

NEW YORK, July 23, 2025 /PRNewswire/ -- J.F. Lehman & Company ("JFLCO"), a leading alternative asset manager focused exclusively on the aerospace, defense, maritime, government, environmental and infrastructure sectors, announced today that investment affiliates have sold Narda AcquisitionCo., Inc. ("Narda-MITEQ" or the "Company") to Amphenol Corporation ("Amphenol", NYSE: APH). Terms of the transaction were not disclosed.Narda-MITEQ is a leading global designer and manufacturer of advanced radiofrequency ( ...